Association of Renin-Angiotensin System Inhibition With Liver-Related Events and Mortality in Compensated Cirrhosis
Clinical Gastroenterology and Hepatology · 2024-02 · 22 (2) · 315-323.e17
DOI: 10.1016/j.cgh.2023.07.009 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Gastroenterology and Hepatology, 2024-02. Verfasst von Hirsh Elhence und 2 weiteren Autor:innen. Beteiligte Einrichtung: Keck School of Medicine, University of Southern California, Los Angeles, California. Hauptthemen laut MEDLINE: Esophageal and Gastric Varices, Renin-Angiotensin System. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAAA NIH HHS, NIDDK NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
BACKGROUND & AIMS: While renin-angiotensin system inhibition lowers the hepatic venous gradient, the effect on more clinically meaningful endpoints is less studied. We aimed to quantify the relationship between renin-angiotensin system inhibition and liver-related events (LREs) among adults with compensated cirrhosis. METHODS: In this national cohort study using the Optum database, we quantified the association between angiotensin-converting enzyme (ACE) inhibitor or angiotensin-receptor blocker (ARB) use and LREs (hepatocellular carcinoma, liver transplantation, ascites, hepatic encephalopathy, or variceal bleeding) among patients with cirrhosis between 2009 and 2019. Selective beta-blocker (SBB) users served as the comparator group. We used demographic and clinical features to calculate inverse-probability treatment weighting-weighted cumulative incidences, absolute risk differences, and Cox proportional hazard ratios. RESULTS: Among 4214 adults with cirrhosis, 3155 were ACE inhibitor/ARB users and 1059 were SBB users. In inverse probability treatment weighting-weighted analyses, ACE inhibitor/ARB (vs SBB) users had lower 5-year cumulative incidence (30.6% [95% confidence interval (CI), 27.8% to 33.2%] vs 41.3% [95% CI, 34.0% to 47.7%]; absolute risk difference, -10.7% [95% CI, -18.1% to -3.6%]) and lower risk of LREs (adjusted hazard ratio [aHR], 0.69; 95% CI, 0.60 to 0.80). There was a dose-response relationship: compared with SBB use, ACE inhibitor/ARB prescriptions ≥1 defined daily dose (aHR, 0.65; 95% CI, 0.56 to 0.76) were associated with a greater risk reduction compared with
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Keck School of Medicine, University of Southern California, Los Angeles, California.
- Department of Population Public Health Sciences, University of Southern California, Los Angeles, Los Angeles, California; Division of Gastroenterology and Liver Diseases, University of Southern California, Los Angeles,…
- Division of Gastroenterology and Liver Diseases, University of Southern California, Los Angeles, California. Electronic address: brian.lee@med.usc.edu.
Förderung
- NIAAA NIH HHS
- NIDDK NIH HHS
- National Institutes of Health
- National Institute on Alcohol Abuse and Alcoholism
Zitieren
APA
Elhence, H., Dodge, J. L., & Lee, B. P. (2024). Association of Renin-Angiotensin System Inhibition With Liver-Related Events and Mortality in Compensated Cirrhosis. Clinical Gastroenterology and Hepatology, 22(2), 315-323.e17. https://doi.org/10.1016/j.cgh.2023.07.009
Vancouver
Elhence H, Dodge JL, Lee BP. Association of Renin-Angiotensin System Inhibition With Liver-Related Events and Mortality in Compensated Cirrhosis. Clinical Gastroenterology and Hepatology. 2024;22(2):315-323.e17. doi:10.1016/j.cgh.2023.07.009
BibTeX
@article{Elhence2024,
author = {Elhence, Hirsh and Dodge, Jennifer L and Lee, Brian P},
title = {Association of Renin-Angiotensin System Inhibition With Liver-Related Events and Mortality in Compensated Cirrhosis},
journal = {Clinical Gastroenterology and Hepatology},
year = {2024},
volume = {22},
number = {2},
pages = {315--323.e17},
doi = {10.1016/j.cgh.2023.07.009}
}
EUVIMED